Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 4
Treatment-assignment count: 0
Stratification count: 0
Low Public Signal
ALK fusion
melanoma · Immune Checkpoint Inhibitor
ALK fusion is flagged as low public signal because public trials show inclusion required evidence in 4 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02978625 | https://clinicaltrials.gov/study/NCT02224781 | https://clinicaltrials.gov/study/NCT05302921 | https://clinicaltrials.gov/study/NCT02304458